Stability and Sterility of Bevacizumab after Withdrawal into a Syringe and Refrigeration or Freezing

Purpose: The aim of this study was to evaluate the stability and sterility of bevacizumab (Avastin, Genentech, Inc., San Francisco, CA, USA) after withdrawal into multiple doses from single-use vials. Methods: Bevacizumab was repeatedly and aseptically drawn from new vials into 1 cc plastic syringes and refrigerated in the dark at 4°C for 0, 3, 6, 12, 28, 38, 46, 52, or 63 weeks or at -10°C for 0, 3, 6, 12, 38, 46, or 52 weeks. The stability of...